Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc." Results 41 - 60 of 219
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
7 Jun 2019, 7:39 am by Samuel B. Friedman, Esq.
Merrell Dow Pharmaceuticals, Inc.[2], the Court ruled that Rule 702 of the Federal Rules of Evidence did not incorporate the Frye general acceptance test as a basis for assessing scientific testimony. [read post]
22 Jan 2019, 2:30 am by Tinker Ready
Ryan Gabrielson ProPublica Originally published at ProPublica January 17 , 2019 At the FBI Laboratory in Quantico, Virginia, a team of about a half-dozen technicians analyzes pictures down to their pixels, trying to determine if the faces, hands, clothes or cars of suspects match images collected by investigators from cameras at crime scenes. [read post]
28 Dec 2018, 2:22 pm by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), appealed a Ninth Circuit ruling that the Frye rule survived, and was incorporated into, the enactment of a statutory evidentiary rule, Rule 702. [read post]
17 Nov 2018, 12:10 pm by Schachtman
To be sure, judges have often poorly expressed their reasoning for deciding scientific evidentiary issues, and perhaps poor communication or laziness by judges was responsible for Rothman’s interest in joining the Daubert fray. [read post]
31 Oct 2018, 10:04 am by Schachtman
In some instances, especially in studies pharmaceutical adverse outcomes, there is the danger that the hypothesized outcome is also a feature of the underlying disease being treated. [read post]
28 Dec 2017, 2:18 pm by Schachtman
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
21 Oct 2017, 9:00 am by W.F. Casey Ebsary, Jr.
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), General Electric Co. v. [read post]
27 Jul 2017, 2:00 am
MERRELL DOW PHARMACEUTICALS, INC 509 U.S. 579 (1993)KOKKONEN V. [read post]
13 Jun 2017, 4:00 am by Jeff Welty
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), where the Supreme Court ruled that, under the federal evidence rules, “the trial judge must ensure that any and all scientific testimony or evidence admitted is not only relevant, but reliable” in light of several factors enumerated by the Court. [read post]